Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + docetaxel
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
pemetrexed + docetaxel is a combination chemotherapy regimen investigated by the University of Arizona in a Phase I dose-escalation trial for patients with advanced solid tumors. Pemetrexed (Alimta) is a multi-targeted antifolate that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby disrupting the synthesis of purines and pyrimidines required for DNA and RNA replication. Docetaxel (Taxotere) is a taxane that binds to and stabilizes microtubules, preventing their depolymerization and leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. The combination was studied on a biweekly dosing schedule in various cancers, including breast, esophageal, gastric, head and neck, non-small cell lung, ovarian, and prostate cancers.
- Brand names
- Alimta + Taxotere
- Other names
- pemetrexed disodium + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))BCL-2 (BCL-2 family)GART (GAR transformylase)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + docetaxel.